Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to $15.0 million.

  • Tg Therapeutics' Accumulated Expenses rose 4887.46% to $15.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year increase of 4887.46%. This contributed to the annual value of $15.2 million for FY2024, which is 2475.35% up from last year.
  • According to the latest figures from Q3 2025, Tg Therapeutics' Accumulated Expenses is $15.0 million, which was up 4887.46% from $10.6 million recorded in Q2 2025.
  • Tg Therapeutics' 5-year Accumulated Expenses high stood at $15.2 million for Q4 2024, and its period low was $1.6 million during Q1 2022.
  • Moreover, its 5-year median value for Accumulated Expenses was $8.3 million (2023), whereas its average is $7.8 million.
  • In the last 5 years, Tg Therapeutics' Accumulated Expenses surged by 15855.26% in 2021 and then tumbled by 6657.33% in 2022.
  • Quarter analysis of 5 years shows Tg Therapeutics' Accumulated Expenses stood at $10.2 million in 2021, then fell by 17.06% to $8.4 million in 2022, then soared by 44.35% to $12.2 million in 2023, then grew by 24.75% to $15.2 million in 2024, then fell by 1.13% to $15.0 million in 2025.
  • Its last three reported values are $15.0 million in Q3 2025, $10.6 million for Q2 2025, and $5.1 million during Q1 2025.